Physician profile
Maurice Schuetz
NPI 1922015767
$581.82
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $123 · 2020: $28.01 · 2021: $61.22 · 2022: $146 · 2023: $199 · 2024: $24.74.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $224.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $223.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacyclics LLC, An Abbvie Company | $204.87 | 2019-2023 | Imbruvica |
| Merck Sharp & Dohme LLC | $98.57 | 2019-2024 | Lynparza, Keytruda |
| Astrazeneca Pharmaceuticals LP | $51.54 | 2023 | Imfinzi, Lynparza |
| Novartis Pharmaceuticals Corporation | $30.33 | 2019-2022 | |
| Amgen INC. | $29.49 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $25.86 | 2022 | |
| Beigene USA, INC. | $20.73 | 2023 | Brukinsa |
| Bayer Healthcare Pharmaceuticals INC. | $19.95 | 2019 | |
| G1 Therapeutics, INC. | $17.93 | 2023 | Cosela |
| Agios Pharmaceuticals, INC. | $15.08 | 2019 | |
| Eisai INC. | $14.91 | 2020 | |
| Mirati Therapeutics, INC. | $14.11 | 2023 | Krazati |
| Emd Serono, INC. | $13.64 | 2021 | |
| Clovis Oncology, INC. | $12.98 | 2019 | |
| Arbor Pharmaceuticals, INC. | $11.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maurice Schuetz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.